More than 96% of registered suicides in both subjects belong to the three generations above 20, and people under 19 account for fewer than 4% of cases – 87 deaths in St Petersburg across seven years – so whatever happens in the youngest group cannot move the regional rate in either direction.

Trials of cognitive behavioural therapy for self-harm recruited unselected patients, so the high-risk label is not what makes that treatment available.

Eight questionnaires have been checked against a clinical interview for binge-eating disorder in adults living with higher weight, while atypical anorexia nervosa, purging disorder and night eating syndrome have one questionnaire each, and in adolescents the tested ground stops at binge eating and loss of control.

A one-point rise in a seven-item questionnaire score doubled the odds that a woman would be taking a GLP-1 six months later, 2.00 (95% CI 1.27 to 3.15), while her body mass index, in the same model with the same controls, did not reach significance, 1.05 (0.99 to 1.11).

The authors state their own conclusion this way: valproate exposure was associated with an increased risk of polycystic ovary syndrome in women with bipolar disorder or epilepsy, with the strongest associations observed for current cumulative exposure and additional risk apparent at high cumulative dosages, while overall cumulative exposure showed a less clear dose-response pattern.

The authors conclude that "Data suggest a favorable benefit-risk profile for AOM 400 versus placebo as a long-term maintenance treatment for BP-I", and all four of the paper's benefit-harm ratios are built on who stopped attending, while the akathisia in 21.2% of patients and the weight gain in 23.5% are printed one table earlier and never enter them.

The outcome here is an admission recorded by a national register rather than anything a patient or a clinician rated, and the deaths of 4,565 people in the cohort were used to end observation rather than counted as an outcome.

The outcome here is a death certificate rather than a craving score, and it shows that a patient admitted to a narcology ward carries three times the all-cause mortality of a low-risk drinker, with a modelled ninefold for external causes that rests on 20 deaths and a very wide confidence interval, from 2.63 to 33.3.

Of 4,674,515 eligible visits in 2019, 73 percent carried a screening; of the 128,996 positive screens, 16,094 people reached the brief intervention step.

The appendix the national template reserves for assessment scales, questionnaires and other instruments for evaluating the patient's state, as printed in full: not provided.

The sentence the authors placed in their conclusion and not in their abstract: lithium treatment should neither be withheld nor continued reflexively solely on the basis of renal concerns, and what replaces the reflex is an individualized, trajectory-based assessment that balances substantial therapeutic benefit against renal risk, preserving lithium's role as a first-line treatment while safeguarding long-term patient health.

The trial is called Screen, Treat and Retain, and retention in methadone treatment is neither among the outcomes it reports nor among the sixteen it registered: what it reports is methamphetamine-negative urine, twice a week, for 25 weeks.

This trial has no objective sleep outcome at all: the registered actigraphy was usable in 22.3% of dyads at 8 months, and every reported number came from the unmasked family carer.

At the site itself the count is 48 deaths in the five years before the barrier and 2 in the seventeen and a half years after. Across Toronto, bridge-related suicide fell 49% in the quarter after completion (IRR 0.51, 95% CI 0.30 to 0.86) and did not rebound over the following seventeen years (IRR 0.99, 95% CI 0.96 to 1.03), with no measured shift to other methods (IRR 1.04, 95% CI 0.90 to 1.20).

The line answers 532 calls a day, which the ministry reports as 92 percent of its daily answering ceiling of 580, while the calls arriving average 1,118 a day.

Britain can count the pens it dispenses and the money they cost, and it took a telephone survey of 5,893 households to establish that about 1.6 million adults have used these drugs for weight loss and another 3.3 million would consider it. 15.0% of users named a product not licensed for weight loss, and interest runs at 11.7% among people finding it very difficult to manage financially against 4.5% among those living comfortably.

The scheme has run since fiscal 2014 and stands at eight designated hospitals across 47 prefectures, and the year it reports is counted in 2,425 contacts, 2,045 of them first-time, set beside a national estimate of approximately 220,000 people with an eating disorder.

The authors' head conclusion is that mono- and combination therapy exhibited substantial heterogeneity in their effectiveness for preventing psychiatric hospitalisation, and that hospitalisation, together with hospitalisation of any cause, is the whole of what this publication measures.

A switch or augmentation of therapy is required by no less than a third of patients taking antipsychotics, the author concludes on pages 31 to 32, and quetiapine is perceived by psychiatrists as a highly effective and well tolerated antipsychotic with a broad spectrum of action going beyond the official indications; his own closing sentence adds that doctors' ideas about the antiresistant properties of the drug require confirmation in real clinical practice and in randomised trials. The article is sponsored by NovaMedica, and a patient entered the programme only if the treating doctor had already decided on quetiapine.

The waiver disappeared and the share of newly diagnosed adults given buprenorphine moved from 18.8% to 19.6%, while retention, overdose and death were not measured at all.

After page 12 the report gives no mortality figure at all: not in the results, not in the overview, not in the conclusion, not in the appendices.

The unit of this toolkit is a row – a statement about the service, a yes or a no, the date it will be looked at again, and a line for what the service intends to do.

Five modules run in the order clinical contact unfolds – recognise, screen, respond, refer, support – and NEDC has approved the whole five hours as the introductory training required for the ANZAED Eating Disorder Credential.

The guideline times every taper to the week and specifies immediate withdrawal when the liver or the blood count says so; for planned stopping of maintenance treatment, sections 1.7 and 1.10 name no threshold in episodes or months of remission and leave the moment inside a required conversation.

The programme counts completions, preceptors and prescribers; its own report measures neither retention in treatment nor overdoses nor deaths, and names retention once, among next year's plans.

The manual is a content base, not a stand-alone intervention: the largest iSupport trial to date found no separation from usual care when carers were left to work through it alone.